SK Biopharm Epilepsy Treatment New Drug 'Cenobamate' Enters European Market

SK Biopharm's new epilepsy treatment drug 'Cenobamate' US launch product 'Xcopri' (Photo by SK Biopharm)

[Asia Economy Reporter Chunhee Lee] SK Biopharm's new epilepsy treatment drug, 'Cenobamate,' has been launched in the European market.

SK Biopharm's partner, Angelini Pharma, announced that Cenobamate was first released in Germany earlier this month under the European product name 'OntozryTM (ONTOZRY®).' Cenobamate is an epilepsy treatment independently developed by SK Biopharm. Following its successful establishment in the world's largest pharmaceutical market, the United States, last year under the product name 'Xcopri® (XCOPRI®),' it has now achieved entry into Europe, the world's second-largest market, in about a year.

Germany is the largest pharmaceutical market in Europe and is considered a foothold for European expansion. According to the global research firm Decision Resources Group, it is estimated that there are approximately 400,000 epilepsy patients in Germany.

Ontozry was launched just two months after obtaining marketing authorization from the European Union (EU) Commission (EC) in March, accelerating its push into the European market. On the 4th, it also received marketing approval from the UK Medicines and Healthcare products Regulatory Agency, bringing its entry into the UK market within reach.

As Ontozry's sales expand in Europe, SK Biopharm is expected to secure sales royalties and milestone revenues linked to sales performance from Angelini Pharma.

This content was produced with the assistance of AI translation services.